NDC 59572-515

Abecma

Idecabtagene Vicleucel

Abecma is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Celgene Corporation. The primary component is Idecabtagene Vicleucel.

Product ID59572-515_1d76d5fe-64a7-4b3b-8675-bcf43bdb7ed7
NDC59572-515
Product TypeCellular Therapy
Proprietary NameAbecma
Generic NameIdecabtagene Vicleucel
Dosage FormSuspension
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-03-26
Marketing CategoryBLA /
Application NumberBLA125736
Labeler NameCelgene Corporation
Substance NameIDECABTAGENE VICLEUCEL
Active Ingredient Strength300000000 1/1
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 59572-515-01

1 SUSPENSION in 1 BAG (59572-515-01)
Marketing Start Date2021-03-26
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Abecma]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ABECMA
ABECMA
90300803 not registered Live/Pending
Celgene Corporation
2020-11-05
ABECMA
ABECMA
90300795 not registered Live/Pending
Celgene Corporation
2020-11-05
ABECMA
ABECMA
88578888 not registered Live/Pending
Celgene Corporation
2019-08-14
ABECMA
ABECMA
88202247 not registered Live/Pending
Celgene Corporation
2018-11-21

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.